Resultados clínicos de perros con tumores cutáneos de mastocitos de alto grado
21 enero, 2025
Resultados clínicos de perros con tumores cutáneos de mastocitos de alto grado
Siew Mei Ong1,2*, Charly McKenna3, Christopher Pinard3,4,5,6, Danielle
Richardson3 y Michelle L. Oblak3*
1 Department of Companion Animal Medicine and Surgery, Faculty of
Veterinary Medicine, Universiti Putra Malaysia, Serdang, Malaysia
2 UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience,
Universiti Putra Malaysia, Serdang, Malaysia
3 Department of Clinical Studies, Ontario Veterinary College, University
of Guelph, Guelph, ON, Canada
4 Department of Oncology, Lakeshore Animal Health Partners,
Mississauga, ON, Canada
5 Centre for Advancing Responsible & Ethical Artificial Intelligence,
University of Guelph, Guelph, ON, Canada
6ANI.ML Research, ANI.ML Health Inc., Toronto, ON, Canada
Resumen
Objetivos
Evaluar los factores pronósticos y el resultado del tratamiento en perros con mastocitomas cutáneos de alto grado (MTCAG).
Métodos
Se revisaron los historiales médicos, en una única institución, de perros con diagnóstico histopatológico de MTCAG . Se documentaron los factores clínicos, las variables relacionadas con el tratamiento y las terapias adyuvantes para evaluar su asociación con los resultados clínicos. Se realizaron análisis comparativos y de supervivencia mediante el análisis de supervivencia de Kaplan-Meier, log-rank y la prueba de probabilidad exacta de Fisher.
Resultados
La media de supervivencia global para los 77 perros fue de 317 días (rango 20-3041 días), con medidas de supervivencia a los 6 meses, 1 año y 2 años del 69%, 50% y 30%, respectivamente. Los perros tratados
quirúrgicamente tuvieron una supervivencia significativamente más prolongada y una probabilidad 6,88 veces mayor de sobrevivir más allá de los 5,5 meses. La presencia de metástasis en la estadificación
inicial se asoció en gran medida con peores resultados, ya que los perros sin metástasis en la estadificación inicial tenían 6,94 veces más probabilidades de sobrevivir más de los 2 años. Las cirugías con márgenes incompletos presentaron una mayor tasa de recurrencia local (58%) en comparación con aquellas con márgenes limpios (26%). A pesar del tratamiento agresivo, el 75% de los perros
que recibieron concurrentemente terapia quirúrgica y adyuvante experimentaron progresión de la enfermedad. La extirpación de ganglios linfáticos, la localización del tumor, el número de tumores y
la recurrencia local no se asociaron con el resultado general.
Descargar trabajo aquí
Bibliografía
1. Galli, SJ, Nakae, S, and Tsai, M. Mast cells in the development of adaptive immune responses. Nat Immunol. (2005) 6:135–42. doi: 10.1038/ni1158
2. Elieh Ali Komi, D, Wöhrl, S, and Bielory, L. Mast cell biology at molecular level: a comprehensive review. Clin Rev Allergy Immunol. (2016) 58:342–65. doi: 10.1007/s12016-019-08769-2
3. London, CA, Kisseberth, WC, Galli, SJ, Geissler, EN, and Helfand, SC. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J Comp Pathol. (1996) 115:399–414. doi: 10.1016/S0021-9975(96)80074-0
4. London, CA, Galli, SJ, Yuuki, T, Hu, ZQ, Helfand, SC, and Geissler, EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol. (1999) 27:689–97. doi: 10.1016/S0301-472X(98)00075-7
5. Letard, S, Yang, Y, Hanssens, K, Palmérini, F, Leventhal, PS, Guéry, S, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. (2008) 6:1137–45. doi: 10.1158/1541-7786.MCR-08-0067
6. Downing, S, Chien, MB, Kass, PH, Moore, PF, and London, CA. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c- kit in mast cell tumors of dogs. Am J Vet Res. (2002) 63:1718–23. doi: 10.2460/AJVR.2002.63.1718
7. Bostock, DE. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J. (1986) 142:1–19. doi: 10.1016/0007-1935(86)90002-3
8. Villamil, JA, Henry, CJ, Bryan, JN, Ellersieck, M, Schultz, L, Tyler, JW, et al. Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms. J Am Vet Med Assoc. (2011) 239:960–5. doi: 10.2460/JAVMA.239.7.960
9. Rothwell, TL, Howlett, CR, Middleton, DJ, Griffiths, DA, and Duff, BC. Skin neoplasms of dogs in Sydney. Aust Vet J. (1987) 64:161–4. doi: 10.
10. Patnaik, AK, Ehler, WJ, and MacEwen, EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. (1984) 21:469–74. doi: 10.1177/030098588402100503
11. Murphy, S, Sparkes, AH, Brearley, MJ, Smith, KC, and Blunden, AS. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec. (2004) 154:743–6. doi: 10.1136/VR.154.24.743
12. Howard, EB, Sawa, TR, Nielsen, SW, and Kenyon, AJ. Mastocytoma and gastroduodenal ulceration: gastric and duodenal ulcers in dogs with mastocytoma. Vet Pathol. (1969) 6:146–58. doi: 10.1177/030098586900600205
13. Ishiguro, T, Kadosawa, T, Takagi, S, Kim, G, Ohsaki, T, Bosnakovski, D, et al. Relationship of disease progression and plasma histamine concentrations in 11 dogs with mast cell tumors. J Vet Intern Med. (2003) 17:194–8. doi: 10.
14. O’Keefe, DA, Couto, CG, Burke-Schwartz, C, and Jacobs, RM. Systemic mastocytosis in 16 dogs. J Vet Intern Med. (1987) 1:75–80. doi: 10.
15. Hume, CT, Kiupel, M, Rigatti, L, Shofer, FS, Skorupski, KA, and Sorenmo, KU. Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). J Am Anim Hosp Assoc. (2011) 47:37–44. doi: 10.5326/JAAHA-MS-5557
16. Kiupel, M, Webster, JD, Bailey, KL, Best, S, DeLay, J, Detrisac, CJ, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. (2011) 48:147–55. doi: 10.1177/0300985810386469
17. Takeuchi, Y, Fujino, Y, Watanabe, M, Takahashi, M, Nakagawa, T, Takeuchi, A, et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Vet J. (2013) 196:492–8. doi: 10.1016/J.TVJL.2012.11.018
18. Moore, AS, Frimberger, AE, Taylor, D, and Sullivan, N. Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours. Vet Comp Oncol. (2020) 18:402–8. doi: 10.1111/vco.12565
19. Murphy, S, Sparkes, AH, Blunden, AS, Brearley, MJ, and Smith, KC. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet Rec. (2006) 158:287–91. doi: 10.1136/VR.158.9.287
20. London, CA, and Thamm, DH. Mast cell tumours. Withrow and MacEwen’s small animal clinical oncology. St. Louis: Saunders Elsevier (2013). p. 335–355
21. Hillman, LA, Garrett, LD, de Lorimier, LP, Charney, SC, Borst, LB, and Fan, TM. Biological behavior of oral and perioral mast cell tumors in dogs: 44 cases (1996-2006). J Am Vet Med Assoc. (2010) 237:936–42. doi: 10.2460/JAVMA.237.8.936
22. Preziosi, R, Sarli, G, and Paltrinieri, M. Prognostic value of intratumoral vessel density in cutaneous mast cell tumours of the dog. J Comp Pathol. (2004) 130:143–51. doi: 10.1016/J.JCPA.2003.10.003
23. Kiupel, M, Webster, JD, Kaneene, JB, Miller, R, and Yuzbasiyan-Gurkan, V. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol. (2004) 41:371–7. doi: 10.1354/vp.41-4-371
24. Mullins, MN, Dernell, WS, Withrow, SJ, Ehrhart, EJ, Thamm, DH, and Lana, SE. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998–2004). J Am Vet Med Assoc. (2006) 228:91–5. doi: 10.2460/JAVMA.228.1.91
25. Bae, S, Milovancev, M, Bartels, C, Irvin, VL, Tuohy, JL, Townsend, KL, et al. Histologically low-grade, yet biologically high-grade, canine cutaneous mast cell tumours: a systematic review and meta-analysis of individual participant data. Vet Comp Oncol. (2020) 18:580–9. doi: 10.1111/vco.12581
26. Weisse, C, Shofer, FS, and Sorenmo, K. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc. (2002) 38:71–3. doi: 10.5326/0380071
27. Anderson, K, Pellin, M, Snyder, E, and Clarke, D. Tumor grade and mitotic count are prognostic for dogs with cutaneous mast cell tumors treated with surgery and adjuvant or neoadjuvant vinblastine chemotherapy. Vet Sci. (2024) 11:363. doi: 10.3390/VETSCI11080363
28. Todd, JE, Nguyen, SM, White, J, Langova, V, Thomas, PM, and Tzannes, S. Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs. Can Vet J. (2021) 62:1335–40.
29. Hay, JK, and Larson, VS. Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors. Can Vet J. (2019) 60:1326–30.
30. Chalfon, C, Sabattini, S, Finotello, R, Faroni, E, Guerra, D, Pisoni, L, et al. Lymphadenectomy improves outcome in dogs with resected Kiupel high-grade cutaneous mast cell tumours and overtly metastatic regional lymph nodes. J Small Anim Pract. (2022) 63:661–9. doi: 10.1111/JSAP.13525
31. Pierini, A, Lubas, G, Gori, E, Binanti, D, Millanta, F, and Marchetti, V. Epidemiology of breed-related mast cell tumour occurrence and prognostic significance of clinical features in a defined population of dogs in west-Central Italy. Vet Sci. (2019) 6:53. doi: 10.3390/vetsci6020053
32. Śmiech, A, Ślaska, B, Łopuszyński, W, Jasik, A, Bochyńska, D, and Dąbrowski, R. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. Acta Vet Scand. (2018) 60:70. doi: 10.1186/s13028-018-0424-2
33. Sabattini, SI, Scarpa, F, Berlato, D, and Bettini, GI. Histologic grading of canine mast cell tumor: is 2 better than 3? Vet Pathol. (2015) 52:70–3. doi: 10.1177/0300985814521638
34. Bostock, DE. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract. (1973) 14:27–40. doi: 10.
35. Donnelly, L, Mullin, C, Balko, J, Goldschmidt, M, Krick, E, Hume, C, et al. Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours. Vet Comp Oncol. (2015) 13:70–6. doi: 10.1111/VCO.12021
36. Dores, CB, Milovancev, M, and Russell, DS. Comparison of histologic margin status in low-grade cutaneous and subcutaneous canine mast cell tumours examined by radial and tangential sections. Vet Comp Oncol. (2018) 16:125–30. doi: 10.1111/VCO.12321
37. Liptak, JM. Histologic margins and the residual tumour classification scheme: is it time to use a validated scheme in human oncology to standardise margin assessment in veterinary oncology? Vet Comp Oncol. (2020) 18:25–35. doi: 10.1111/VCO.12555
38. Misdorp, W. Incomplete surgery, local immunostimulation, and recurrence of some tumour types in dogs and cats. Vet Q. (1987) 9:279–86. doi: 10.1080/01652176.1987.9694113
39. Hahn, KA, King, GK, and Carreras, JK. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987–1998). J Am Vet Med Assoc. (2004) 224:79–82. doi: 10.2460/JAVMA.2004.224.79
40. Krick, EL, Billings, AP, Shofer, FS, Watanabe, S, and Sorenmo, KU. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Vet Comp Oncol. (2009) 7:130–8. doi: 10.
41. Marconato, L, Polton, G, Stefanello, D, Morello, E, Ferrari, R, Henriques, J, et al. Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumours. Vet Comp Oncol. (2018) 16:580–9. doi: 10.1111/vco.12425
42. Baginski, H, Davis, G, and Bastian, RP. The prognostic value of lymph node metastasis with grade 2 MCTs in dogs: 55 cases (2001–2010). J Am Anim Hosp Assoc. (2014) 50:89–95. doi: 10.5326/JAAHA-MS-5997
43. Ran, S, Volk, L, Hall, K, and Flister, MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology. (2010) 17:229–51. doi: 10.
44. Worley, DR. Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures. Vet Comp Oncol. (2014) 12:215–26. doi: 10.
45. Ferrari, R, Chiti, LE, Manfredi, M, Ravasio, G, De Zani, D, Zani, DD, et al. Biopsy of sentinel lymph nodes after injection of methylene blue and lymphoscintigraphic guidance in 30 dogs with mast cell tumors. Vet Surg. (2020) 49:1099–108. doi: 10.1111/VSU.13483
46. Mochizuki, H, Motsinger-Reif, A, Bettini, C, Moroff, S, and Breen, M. Association of breed and histopathological grade in canine mast cell tumours. Vet Comp Oncol. (2017) 15:829–39. doi: 10.1111/VCO.12225
47. Warland, J, and Dobson, J. Breed predispositions in canine mast cell tumour: a single Centre experience in the United Kingdom. Vet J. (2013) 197:496–8. doi: 10.1016/J.TVJL.2013.02.017
48. Sfiligoi, G, Rassnick, KM, Scarlett, JM, Northrup, NC, and Gieger, TL. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990–2001). J Am Vet Med Assoc. (2005) 226:1368–74. doi: 10.2460/JAVMA.2005.226.1368
Date de alta y recibe nuestro 👉🏼 Diario Digital AXÓN INFORMAVET ONE HEALTH
Date de alta y recibe nuestro 👉🏼 Boletín Digital de Foro Agro Ganadero
Noticias animales de compañía
Noticias animales de producción
Trabajos técnicos animales de producción
Trabajos técnicos animales de compañía
—